• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BridgeBio Pharma Inc. (Amendment)

    1/23/24 10:16:16 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBIO alert in real time by email
    SC 13G/A 1 Bridgebio_Pharma_Inc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING BRIDGEBIO PHARMA INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 10806X102 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO:10806X102 13G Page 2 of 5 Pages 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 4,757,733 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 5,086,899 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,086,899 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.92% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 10806X102 13G Page 3 of 5 Pages ITEM 1. (A) NAME OF ISSUER BRIDGEBIO PHARMA INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 421 KIPLING STREET PALO ALTO CA 94301 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER 1 CONGRESS STREET, SUITE 1 BOSTON, MA 02114-2016 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 10806X102 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO:10806X102 13G Page 4 of 5 Pages ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS YES ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO:10806X102 13G Page 5 of 5 Pages ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION.
    Get the next $BBIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BBIO

    DatePrice TargetRatingAnalyst
    7/21/2025$66.00Buy
    Truist
    7/14/2025$70.00Buy
    Jefferies
    7/9/2025$60.00Perform → Outperform
    Oppenheimer
    6/17/2025$49.00Outperform
    Wolfe Research
    3/31/2025$50.00Buy
    Redburn Atlantic
    10/16/2024Sector Outperform
    Scotiabank
    10/3/2024Perform
    Oppenheimer
    9/4/2024$46.00Overweight
    Piper Sandler
    More analyst ratings

    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

      4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:49:25 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

      4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:46:18 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      2/13/24 4:00:10 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

      Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

      11/25/24 8:41:11 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Financials

    Live finance-specific insights

    See more
    • BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

      PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will b

      7/22/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

      PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be a

      4/22/25 7:30:37 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

      - As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first

      2/20/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      11/6/24 5:04:05 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      9/17/24 6:41:54 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      8/20/24 8:42:04 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

      - By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates1 (3.9 per 100,000), which equates to approximately 25,000 carriers of ADH1-causing variants in the US and EU - Only ~20% of individuals with genetic variants linked to ADH1 were found to have an established diagnosis, highlighting a major gap in disease recognition and care - Nine novel gain-of-function CASR variants were identified, which were associated with a symptom burden consistent with the known clinical presentation of ADH1 - The findings show an allelic series, indic

      7/23/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

      PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will b

      7/22/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

      Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company ("SPAC") sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the "Registration Statement"), filed by Helix and BBOT, relating to the previously-announced b

      7/11/25 7:43:00 AM ET
      $BBIO
      $HLXB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Kumar Neil sold $3,410,450 worth of shares (80,000 units at $42.63) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      7/3/25 4:30:19 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Viking Global Investors Lp sold $154,000,000 worth of shares (3,500,000 units at $44.00) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      7/1/25 7:48:36 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Homcy Charles J gifted 20,000 shares, decreasing direct ownership by 2% to 1,216,674 units (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      6/30/25 5:54:20 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on BridgeBio Pharma with a new price target

      Truist initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $66.00

      7/21/25 8:31:03 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on BridgeBio Pharma with a new price target

      Jefferies initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $70.00

      7/14/25 8:47:47 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded BridgeBio Pharma from Perform to Outperform and set a new price target of $60.00

      7/9/25 8:08:10 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

      SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      7/1/25 7:49:36 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BridgeBio Pharma Inc.

      144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

      7/1/25 4:31:44 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BridgeBio Pharma Inc.

      144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

      7/1/25 4:31:30 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

      PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope

      7/23/24 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

      The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci

      5/2/24 7:00:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

      PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation

      10/25/21 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care